Cellular Biomedicine Group Reports First Quarter 2016 Financial Results and Provides Business Highlights
May 09, 2016 16:01 ET
|
Cellular Biomedicine Group Inc.
– Reported Positive Clinical Data from Phase IIb trial of ReJoin® haMPC therapy– Expanded Stem Cell Platform with the Launch of New Allogeneic Clinical Trial– Closed Strategic Investment of $43.13...
Cellular Biomedicine Group Announces Closing of $43.13 Million Strategic Investment from Dangdai International Group Co., Limited, a Wholly-Owned Hong Kong Subsidiary of Wuhan Dangdai Science & Technology Industries Group Inc.
April 19, 2016 08:30 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biomedicine...
Cellular Biomedicine Group Reports Full-Year 2015 Financial Results and Recent Operational Progress
March 14, 2016 07:00 ET
|
Cellular Biomedicine Group Inc.
- Achieved first clinical milestones for CD19, CD20, CD30 and EGFR CAR-T cell assets- Expanded Immuno-Oncology platform with key acquisitions- Expanded Stem Cell platform with the launch of new...
Cellular Biomedicine Group Announces a $43.13 Million Strategic Investment From Dangdai International Group Co., Limited, a Wholly Owned Hong Kong Subsidiary of Wuhan Dangdai Science & Technology Industries Group Inc.
February 04, 2016 09:08 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group Announces Chairman of the Board of Directors, and Appointment of Chief Executive Officer
January 28, 2016 06:00 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Jan. 28, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group Announces Positive 48-Week Data From Phase IIb Clinical Trial for Knee Osteoarthritis Stem Cell ReJoin® Therapy
January 13, 2016 08:00 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Jan. 13, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group Announces CEO Transition
January 11, 2016 09:00 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group Selected to Present at Biotech Showcase™ 2016
January 08, 2016 09:00 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group Launches Phase I Clinical Trial for AlloJoin™ Off-the-Shelf Allogeneic Stem Cell Therapy for Knee Osteoarthritis
January 06, 2016 09:03 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group Announces Upcoming Presentation to Release 48-Week Data From Phase IIb Clinical Trial for Knee Osteoarthritis ReJoin® Stem Cell Therapy
December 22, 2015 09:00 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...